Navigation Links
Pharmasset Reports Fiscal Year End 2009 Financial Results
Date:11/25/2009

PRINCETON, N.J., Nov. 25 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported financial results for the fiscal year ended September 30, 2009. At September 30, 2009 Pharmasset held $58.4 million in cash, cash equivalents and short term investments.

Pipeline Update and 2009 Highlights

RG7128

Phase 2b Trial

In late November 2009, an independent Data Monitoring Committee (DMC) reviewed the safety and efficacy data from the first approximately 100 patients in cohort 1 and concluded that based on these data the remaining approximately 300 patients can be safely enrolled in the phase 2b study. The DMC reviewed any potential drug discontinuations, incidence and details of adverse events, and selected laboratory assessments. No safety events in the DMC review were considered significantly different from those expected from HCV patients taking peginterferon and ribavirin treatment. The DMC did not recommend modification of dose or duration of any RG7128 dosing regimens. Enrollment of these patients pre-screened for this cohort in the fourth quarter of 2009 has begun and is expected to be complete by the end of the first quarter of 2010.

This phase 2b trial is anticipated to enroll approximately 400 treatment-naive, genotype-1 or genotype-4 HCV-infected patients. The five arm trial, initiated in April 2009, is evaluating the dose and duration of RG7128 in combination with peginterferon plus ribavirin. The primary efficacy endpoint of the trial is the proportion of patients that achieve a sustained virologic response (SVR).

In the first quarter 2010, Roche plans to initiate longer duration, phase 2b studies with
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
2. Pharmasset to Present at Lazard Capital Markets Healthcare Conference
3. Pharmasset Reports Positive Preliminary Antiviral Data With PSI-7851 for the Treatment of Hepatitis C
4. Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
5. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
6. Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
7. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
8. Pharmasset Reports Fiscal Year End 2008 Financial Results
9. Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
10. Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
11. Pharmasset to Present at the UBS Global Life Sciences Conference on Wednesday, September 24th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Mallinckrodt plc (NYSE: ... announced that it has completed its acquisition of ... $2.3 billion. The Ikaria acquisition extends Mallinckrodt,s footprint ... into neonatal critical care with INOMAX ® ... a highly vulnerable patient population. It also accelerates ...
(Date:4/16/2015)... , April 16, 2015  Diplomat Pharmacy, Inc. ... Shannon Beltrand to their senior leadership team as ... be responsible for securing and properly monitoring Diplomat,s data, ... both internally and externally. Additionally, she will play key ... "We are very excited to have someone ...
(Date:4/16/2015)... YORK , April 16, 2015 An ... additional way to generate trimers from the major HIV ... could benefit future clinical development of HIV vaccine candidates ... the critical target on the surface of HIV for ... an important platform for AIDS vaccine discovery, says ...
Breaking Medicine Technology:Mallinckrodt Completes Acquisition Of Ikaria 2Mallinckrodt Completes Acquisition Of Ikaria 3Mallinckrodt Completes Acquisition Of Ikaria 4Mallinckrodt Completes Acquisition Of Ikaria 5Diplomat Names Shannon M. Beltrand as New CISO 2New Method Holds Promise for HIV Vaccine Development 2
(Date:4/17/2015)... Rapids, MI (PRWEB) April 17, 2015 Enthusiasts ... CRUSH Grand Rapids, Saturday, April 25, 2015. The event will ... Reserve Wine & Food (201 Monroe Ave NW, Grand Rapids, ... from around the West Michigan area. Patrons are encouraged to ... of elegance and fun. , This year’s event will feature ...
(Date:4/17/2015)... York (PRWEB) April 17, 2015 ... allege this class of prescription medications increases the ... attack, stroke or other life-threatening cardiovascular event continue ... U.S. District Court, Northern District of Illinois. According ... U.S. Judicial Panel on Multidistrict Litigation (JPML) on ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 The American College of ... and Free Application Day on April 29. The event will be ... Square, located at 555 DeHaro St. in San Francisco, CA. , ... – Check in at the DeHaro campus (room F), 11:10 a.m. ... of campus, Noon – Light lunch with current students, faculty and ...
(Date:4/17/2015)... Carolina (PRWEB) April 17, 2015 With ... Dental Care has spent the last four years ... care, performing procedures ranging from general cleanings to dental ... a grand opening at their new office in North ... same services as their Concord office, including denture fittings, ...
(Date:4/17/2015)... April 17, 2015 Mario ... polish and perfect facial skin with its unique ... and blend of energizing botanicals. This cushiony gel-based ... that cause breakouts and inhibit penetration of special ... Ecuadorian Ivory Palm Seeds, This uncommon exfoliating ingredient ...
Breaking Medicine News(10 mins):Health News:Children’s Leukemia Foundation of Michigan Presents 3rd Annual CRUSH Grand Rapids 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 2Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 3Health News:Testosterone Treatment Lawsuits Increase, as New Report Indicates Over 200 Federal Cases Filed Since March 4Health News:American College of Traditional Chinese Medicine Hosts Open House 2Health News:Mario Badescu Skin Care Launches Botanical Exfoliating Scrub 2
... weight loss and preventive cardiology. The unique medical practice will offer ... pantry makeovers. , ... Denver, CO (PRWEB) August 10, ... change the way the medical community treats obesity by improving patients, ...
... Cryoablation attractive option for older patients with other medical ... News) -- A new method of freezing damaged cells ... is being used by gastroenterologists at the University of ... condition called Barrett,s esophagus can result from ongoing heartburn, ...
... selected iCRco, an American CR Company, as its new Digital Imaging ... diagnoses for our troops injured in battle. , ... ... an American CR Company, as its new Digital Imaging provider. iCRco,s ...
... Investor Conference Call on Monday, August 11, 2008 at 8:30am ... ... 8 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ), a biopharmaceutical company focused ... treatment of life-threatening,diseases, including renal disease and cancer, today announced its results,for ...
... Inc., administrator for the,HealthShares(TM) Indexes, a series ... Traded Funds, today announced the following changes,effective ... August 11, 2008: Enzo Biochem,Inc. will replace ... the,HealthShares(TM) Infectious Disease Index and the HealthShares(TM),Composite ...
... MedQuist,Inc.,(Nasdaq: MEDQ ) the largest Medical Transcription Service ... the quarter ended June,30, 2008. Revenue for the second ... in the second quarter of 2007. The decrease in ... period was primarily due to,customer losses experienced during the ...
Cached Medicine News:Health News:Weight Loss and Disease Prevention Head Home 2Health News:New Therapy Freezes Out Esophageal Cancers 2Health News:US Military Chooses American Made iCRco Digital Radiography Systems 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 2Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 3Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 4Health News:Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2008 Financial Results 5Health News:Mergent, Inc. Announces Changes to the HealthShares(TM) Infectious Disease and HealthShares(TM) Composite Indexes 2Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9
Visionary OFFICE™ PM offers a Windows interface featuring medical billing, appointment scheduling and patient information....
... Medical Billing system allows a practice ... It is integrated with the EMR, ... system interfaces with electronic clearinghouses for ... a set of reports, it presents ...
... The Infinity Amylase CPNG3 single ... all the convenience of single liquid ... minimize operator error and provide quick ... of the Infinity Amylase CPNG3 reagent ...
... Infinity Uric Acid single liquid stable ... convenience of single liquid stability to ... error and provide quick result turnaround ... Infinity Uric Acid reagent provides a ...
Medicine Products: